Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors

BACKGROUND: HIV-1 typically develops resistance to any single antiretroviral agent. Combined anti-retroviral therapy to reduce drug-resistance development is necessary to control HIV-1 infection. Here, to assess the utility of a combination of antibody and fusion inhibitor treatments, we investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Alam, Muntasir, Kuwata, Takeo, Shimura, Kazuya, Yokoyama, Masaru, Ramirez Valdez, Kristel Paola, Tanaka, Kazuki, Maruta, Yasuhiro, Oishi, Shinya, Fujii, Nobutaka, Sato, Hironori, Matsuoka, Masao, Matsushita, Shuzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037607/
https://www.ncbi.nlm.nih.gov/pubmed/27670680
http://dx.doi.org/10.1186/s12977-016-0304-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037607/
https://www.ncbi.nlm.nih.gov/pubmed/27670680
http://dx.doi.org/10.1186/s12977-016-0304-7

Ejemplares similares